Partners Overview page

Partner with Ambry Genetics

At Ambry Genetics, we are driven to giving healthcare providers the most advanced genetic testing information available so they can determine the best treatment options for their patients. Our partnerships range from and include biopharma companies, academic institutions, clinical collaborations, and nonprofits. We know breakthroughs and advancements in science don’t happen in a vacuum, and we work with each of our partners to drive research forward and accelerate the understanding of human disease. Partner with us and join the expanding collaboration of academic, commercial, and pharmaceutical partners who are as passionate as we are about the potential for genetic testing and its impact on the lives of patients.

Looking for Ambry Genetics Partnerships?

At Ambry Genetics, we understand that our history of firsts to market and our decades-long track record of discoveries wasn't made alone. Along the way, we partnered and collaborated with other leading companies who believe, as we do, that everyone benefits from best-in-class genetic testing and the most accurate interpretation of those results. Some of our Commercial Partnerships include our partnership with Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine. We have also partnered with MDxHealth to increase genetic testing within the urology market. And Volpara Solutions, whose advanced technology platform combines with healthcare providers’ expertise to provide a high-quality, optimized, and personalized cancer screening experience. Learn more about our partnerships by visiting our Commercial Partnerships page.

We also have our CARE Program®, which stands for Comprehensive Assessment, Risk & Education. Ambry’s CARE Program was developed to identify patients at increased risk for cancer - earlier. Patients who are at increased risk for cancer may be candidates for genetic testing, in addition to earlier, more frequent, or additional types of screening or preventive surgical options. Cancer risk assessment and genetic testing programs are critical for identifying patients who may be at increased risk and may benefit from tailored medical management. Visit our CARE page or our CARE for COVID page to learn more.

More About Our No Charge Testing Programs

Our AmbryLink program is a sponsored, no charge, hereditary testing partnership that provides our partners the opportunity to identify rare disease patients quickly and accurately. The program is a comprehensive solution that maximizes patient identification with quality genetic testing, a solid network of relationships at major academic centers, and broad field support to lower testing barriers. Ambry also works with academic and commercial partners so we can better assess clinical validity of gene-disease relationships. This helps us ensure that the results we provide clinicians are as accurate and informative as possible. We care what happens to real people, their families, and the people they love, and remain dedicated to providing deeper knowledge and fresh insights to healthcare providers.

Search Results

Start your search...